Novartis Bounces Back From COVID-19 And Cosentyx Keeps Climbing
Business Nearly Back To Normal
Executive Summary
Sales at the Swiss major have returned to around 80%-90% of their pre-pandemic levels, according to CFO Harry Kirsch after unveiling a healthy set of second-quarter financials.
You may also be interested in...
Novartis China Drive Paying Off, Sales Soar On Reimbursement Inclusion
Sales of the Swiss drug maker's major plaque psoriasis treatment Cosentyx in China quadrupled in the second quarter, despite its price being slashed by more than 60%.
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: J&J’s outlook for coronavirus vaccines; Cosentyx comes in strong for Novartis; Biogen’s views on Aduhelm pricing; competition in the “dustat” sector; and dealing with endemic COVID-19.
Keeping Track: US FDA Clears Bylvay, Fexinidazole, Gives Retifanlimab CRL; JAK Inhibitor Class Delays
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker